Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental design We have investigated in three models of highly epidermal growth factor receptor (EGFR)-dependent colorectal cancer xenografts, the effect of maintenance therapy with different kinase inhibitors alone or in combination with cetuximab, after cytotoxic treatment induction with irinotecan plus cetuximab. Results SW48, LIM 1215, and GEO colorectal cancer cell lines were engrafted into nude mice and treated for 3 weeks with irinotecan and/or cetuximab. The combined treatment induced a significant reduction of tumor size. A subsequent experiment was performed in all three xenograft models in which after an induction treatment with irinotecan plus cetuximab, mice were randomly assigned to one of the following treatments: control, cetuximab, regorafenib, a selective PIK3CA inhibitor (PIK3CAi), a selective MEK inhibitor (MEKi), and/or the combination of each inhibitor with cetuximab. The cetuximab plus MEKi treatment determined the best antitumor activity with suppression of tumor growth. This effect was prolonged for 13 to 15 weeks after cessation of therapy and was accompanied by prolonged survival. Antitumor activity was accompanied by inhibition of the MAPK and MEK pathways. Moreover, in the cetuximab plus MEKi-treated SW48 xenograft group, KRAS mutations as a mechanism of acquired resistance were detected in 25% of cases compared with 75% KRAS…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is exciting that multiple preclinical studies have demonstrated that MEK inhibitors can inhibit the proliferation of CRC cells with KRAS or BRAF mutations in vitro and in vivo, reversing drug resistance mediated by KRAS or BRAF mutations [21,22].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [21]
In the citing paper
“More importantly, the combination of selumetinib and cetuximab failed to achieve positive results in a clinical trial in refractory metastatic CRC patients with KRAS mutations [30, 101]”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [101]
In the citing paper
“Encouragingly, combination treatment with MEK and EGFR inhibitors seems to be a possible strategy to overcome the multifaceted clonal heterogeneity in tumours [29, 101].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [101]
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Theunderstandingofmolecular features of tumors has revealed that cancer genomes are highly heterogeneous especially in the case of metastatic dissemination (39).”
BackgroundDetection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562 · cited 1×
“2 million of new cases expected worldwide every year (1).”
BackgroundPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“In particular, with the extended RAS analysis that covers exons 2,3,4 mutations for KRAS and NRAS genes the benefit of anti-EGFR mAbs to first-line FOLFIRI chemotherapy for the all-RAS wild-type patients has been translated in a further improvement of overall survival (6-10).”
BackgroundKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 5×
“In fact, similar toour results,Misale and colleagues (15)wereunable todetect the LIM 1215 cetuximab-resistant KRAS G12R mutation in the LIM 1215 parental cells implying that this mutation was acquired during treatment.”
BackgroundResultInfluential
Cited by
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.001 · Cited by 146
“This effect was accompanied by significant prolongation of survival in mice with approximately 20% mice being cured [81].”
BackgroundSelf-citationTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
“56 All these alterations converge to activate the principal downstream effector of EGFR pathway: MAPK-ERK, whose EGFR-independent overactivation allows the tumour to survive in the presence of anti-EGFR drugs (figure 2).(88)”
BackgroundSelf-citationCorte, C. M. D., Malapelle, U., Vigliar, E., Pepe, F., Troncone, G., Ciaramella, V., Troiani, T., Martinelli, E., Belli, V., Ciardiello, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15479 · Cited by 46
Self-citation
Metadata
- Authors
- Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., Formisano, L., Bianco, R., Ciardiello, D., & Ciardiello, F.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- 3Pharmacogenomic Laboratory, INT-Fondazione Pascale-Centro di Ricerche Oncologiche di Mercogliano (CROM), Mercogliano (AV), Italy.
- University of Naples Federico II (IT)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2015-09-14
- Volume
- 21
- Issue
- 18
- Pages
- 4153-4164
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1849035610
- Cited by
- 18
- References
- 45
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2017: 3 · 2016: 3 · 2015: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- cetuximab, irinotecan, maintenance therapy, metastatic colorectal cancer, EGFR inhibitors, MEK inhibitors, regorafenib, PIK3CA inhibitors, acquired drug resistance, KRAS mutation, MAPK signaling, xenograft models, combination chemotherapy
- MeSH terms
- Cetuximab, Irinotecan, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cell Survival, Diphenylamine, Drug Synergism, Female, Humans, Mice, Inbred BALB C, Mice, Nude, Mutation, Sulfonamides, Colorectal Neoplasms, Phosphatidylinositol 3-Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0211
- The paper
- Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., Formisano, L., Bianco, R., Ciardiello, D., & Ciardiello, F. (2015). Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.